Home
Resource

DMPK Resource Center

Resource

Knowledge Areas

Knowledge Areas for DMPK Research Support

Bioanalysis

LC-MS/MS Single Drug Quantification Guide

Overcoming Matrix Effects and Analytical Challenges in Small Molecule LC-MS/MS Bioanalysis

Plasma vs Serum for Drug Bioanalysis: Anticoagulant Selection, Pre-Analytical Variables, and Stability-Driven Sample Preparation

Tissue Homogenization for Drug Bioanalysis: Bead Beating, Rotor-Stator, and Enzymatic Digestion Methods Compared

Tissue Drug Quantification by LC-MS/MS: From Solid Tissue to Validated Concentration Data

Cell Lysate Drug Quantification by LC-MS/MS: Intracellular Concentration Analysis from Cell Cultures

Drug Metabolite Quantification by LC-MS/MS: The Complete Guide

Metabolite Identification (MetID) in Drug Discovery: Data Generation, Structural Elucidation, and Trend Analysis

Downstream Metabolite Tracking: LC-MS/MS Methods for Tracing Drug Biotransformation Pathways

Bioanalytical Matrix Stability Testing: Ensuring Analyte Integrity from Collection to LC-MS/MS Analysis

Sample Handling Stability in Bioanalysis: From Blood Collection to LC-MS/MS Injection

Post-Extraction Sample Integrity in LC-MS Bioanalysis: Vial Adsorption Mechanisms, In-Vial Stability, and High-Throughput Queuing Strategies

Degradant Structural Elucidation by LC-MS: High-Resolution Mass Spectrometry Approaches for Identifying Unknown Degradation Products

Advanced Drug Metabolite Identification: HRMS Workflows, Spectral Annotation, and Regulatory Reporting for Preclinical DMPK

Reactive Metabolite Screening and Covalent Binding Assessment in Drug Discovery: GSH Trapping, Cyanide Trapping, and Idiosyncratic Toxicity Risk Stratification

CYP-Mediated Drug-Drug Interaction Assessment: Reversible Inhibition, Time-Dependent Inhibition, and Induction Studies per ICH M12

Transporter-Mediated Drug-Drug Interactions: P-gp, BCRP, OATP, OCT, and MATE Assessment Strategies per ICH M12

PBPK Modeling for Drug-Drug Interaction Prediction: From Static Mechanistic Models to Physiologically-Based Pharmacokinetic Simulations per ICH M12 and M15

Plasma Drug Concentration Fundamentals: What Plasma Levels Mean, How They Are Measured, and the Key Parameters Explained

How to Read and Interpret Plasma Drug Concentration-Time Curves: A Practical Guide to PK Parameter Estimation

Blood-to-Plasma Ratio in Preclinical Drug Development: LC-MS/MS Methods, Interpretation, and PK Implications

Tissue-to-Plasma Ratio (Kp): Determination Methods, Tissue Distribution Study Design, and PBPK Model Integration

Bioanalytical Method Development and Validation for LC-MS/MS Drug Quantification: A Practical Framework

ICH M10 Bioanalytical Method Validation for LC-MS/MS Assays: Key Requirements, Common Pitfalls, and Compliance Strategies

Stability-Indicating Method Development: HPLC and LC-MS Approaches for Drug Stability Testing

Forced Degradation Studies: A Comprehensive Guide for Drug Substance and Drug Product Stability Testing

In Vitro Compound Stability Profiling: Plasma, Microsomal, and Chemical Stability Screening in Drug Discovery

Short-Term and Long-Term Stability Studies in Drug Development: ICH Q1A(R2) Design, Execution, and Regulatory Submission

Freeze-Thaw Stability Testing in Drug Development: From Pharmaceutical Products to Bioanalytical Method Validation

Mass Balance in Forced Degradation Studies: Calculation Methodology, Acceptance Criteria, and Regulatory Documentation per ICH Q1

What Is Small Molecule Bioanalysis? Principles, Workflows, and Applications in Drug Development

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →

Online Inquiry

Quick Links

Contact Us

USA

Tel:

Fax:

Email:

Germany

Copyright © 2026 Creative Proteomics. All rights reserved.